The systemic effects of PM01183 partially mimic those reported by Nissinen et al. [82], showing that blocking the activin receptor type 2 (ACVR2B) ligands efficiently attenuated cachexia, improved survival and reduced splenomegaly in C26-mice, but this was not explained by fewer markers of MDSCs nor by restrained levels of IL-6 or IL-1β. The gene discussed is IL1B; the disease is Splenomegaly.